CELG Stock UPDATES Celgene Corp (CELG) 105.14 10/29/2014 20:

New Post Public Reply Private Reply Replies (0) Message Board

Oct 29, 2014 at 9:12 PM

Celgene Corp (CELG) 105.14 $CELG

Jim Cramer's 'Mad Money' Recap: Where to Find Bargains Created by the Fed
at The Street - 1 hr ago
With the Federal Reserve finally ending its bond buying, there are many stocks that are ready to be bought, not sold, on any Fed-induced weakness, Cramer says.
KMI: 38.33 (-0.84), ETN: 65.92 (+1.14), FB: 75.86 (-4.91), PFE: 29.49 (+0.40), INVN: 16.08 (-5.40), WDC: 95.79 (+2.71), HPQ: 35.38 (-0.16), CVRR: 24.51 (-0.31), CELG: 105.14 (-0.56), EPB: 40.36 (-0.86), ISIS: 45.01 (-1.42), IBM: 163.46 (-0.14), AMAT: 21.47 (+0.22), GOOGL: 558.45 (-0.49), TWTR: 42.08 (-1.70), MSFT: 46.62 (+0.13), IGT: 16.29 (unch), REGN: 387.70 (-10.19), PII: 148.31 (-1.26), BABA: 98.31 (-1.37)

Final Glance: Biotechnology companies
AP - Wed Oct 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Midday Glance: Biotechnology companies
AP - Wed Oct 29, 12:41PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 315.06 (-2.97), CBST: 71.35 (-0.99), MDCO: 25.16 (-0.70), SRPT: 15.19 (+0.07), ALXN: 190.49 (-1.71), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Early Glance: Biotechnology companies
AP - Wed Oct 29, 9:53AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

SmarTrend Watching for Potential Pullback in Shares of Celgene After 2.54% Gain
Comtex SmarTrend(R) - Tue Oct 28, 3:59PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $104.06 to a high of $106.07. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $103.91 on volume of 6.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 105.14 (-0.56)

After Yesterday's Rally of 2.54% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Oct 28, 3:58PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $104.06 to a high of $106.07. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $103.91 on volume of 6.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 105.14 (-0.56)

Stocks Extend Gains As Alibaba, Tesla Rally
at Investor's Business Daily - Tue Oct 28, 11:04AM CDT
Major averages extended their gains in late-morning trading amid earnings reports and a surprisingly strong consumer confidence reading. The Nasdaq rallied 1.2%, the S&P 500 gained 0.6% and the Dow was up 0.4%. Volume was tracking higher on the...
TSLA: 238.10 (-4.67), AMGN: 158.88 (+1.69), AAPL: 107.34 (+0.60), BABA: 98.31 (-1.37), CELG: 105.14 (-0.56)

Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 21.95 (-0.13), AGIO: 79.36 (-1.24), CELG: 105.14 (-0.56)

Amgen Beats Earnings Estimates, What's Next for AMGN? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Oct 27, 11:59PM CDT
Amgen had a solid beat on earnings, and AMGN stock was rising after hours.
GILD: 110.72 (-2.73), AMGN: 158.88 (+1.69), CELG: 105.14 (-0.56)

Four Biotechs Lead Health Care Stocks In Big Cap 20
at Investor's Business Daily - Mon Oct 27, 6:00PM CDT
Medical stocks are flexing their muscles in the latest Big Cap 20 list, as they've more than doubled in number from the prior week. Even though a few medical sectors make the cut, biotechs are well represented. The group earned the top ranking in...
VRX: 129.76 (-1.31), ALXN: 190.49 (-1.71), ILMN: 188.88 (-1.77), AMGN: 158.88 (+1.69), REGN: 387.70 (-10.19), CELG: 105.14 (-0.56)

Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 44.50 (+0.34), NVAX: 5.41 (-0.07), AGIO: 79.36 (-1.24), SNY: 45.22 (-2.85), MNKD: 6.07 (-0.11), CELG: 105.14 (-0.56)

3 Biotech Stocks Growing Faster Than Gilead Sciences Inc.
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 27, 7:03AM CDT
Source: Celgene. Gilead Sciences has captured investors' attention this year thanks to wildly impressive sales of its hepatitis C drug Sovaldi, but the company is by no means the only fast-growing big biotech out there. Gilead's bottom line...
MDVN: 99.55 (-1.63), JNJ: 105.56 (+0.77), BIIB: 315.06 (-2.97), GILD: 110.72 (-2.73), NVS: 91.31 (-1.04), CELG: 105.14 (-0.56)

IBD 50 Stocks Regain Buy Points
at Investor's Business Daily - Fri Oct 24, 5:54PM CDT
The IBD 50 has been the land of the second chance, as many stocks have rebounded from sell signals. In several cases, stocks triggered the 8% sell rule or hit another sell signal. Yet a lot of them have rallied back and reclaimed their buy points....
AKRX: 43.14 (-0.40), ALXN: 190.49 (-1.71), CELG: 105.14 (-0.56)

Celgene Rises 2.83% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Oct 24, 3:42PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $99.21 to a high of $103.31. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $100.91 on volume of 9.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 105.14 (-0.56)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flying Car Regulatory Sandbox Begins in UAE

Pioneering Flying Cars in the Desert In a move that seems right out of a science fiction screenplay, ARIDGE—the bigwig of flying cars from Asia—has taken a giant leap. They’ve cozied up with the UAE, locking arms to cook up the world's first regulatory sandbox for personal flying cars. Now, don’t laugh—sandbox isn't just for toddlers. It’s the playground where...

BarrelPick.com Launches for Bourbon Aficionados

Just when you think you've seen all the ways to enjoy bourbon, along comes BarrelPick.com with a tantalizing new proposition. They're throwing down the gauntlet for bourbon lovers everywhere by letting you buy an entire barrel, let it sit around for a bit, watch it mature, and then call the shots on when it finally sees the light of day in a bottle. Talk about skipping...

Insta360 Expands with Times Square Flagship Store

Insta360 Times Square Opening Marks Bold Expansion I dropped by Times Square today, and what do I see? Insta360 planting its flag right in the heart of New York City. Now, this isn't your run-of-the-mill grand opening—it’s the first flagship store outside of Asia, and it screams of big ambitions. Nestled at 1515 Broadway, the store is smack in the middle of one of the...

Papa John's Faces Class Action Over Misleading Info

Trouble Brewing for Papa John's Investors Rolling the dice in the stock market sometimes feels like playing the lottery, doesn't it? This time around, it's Papa John's (NASDAQ: PZZA) serving up a slice of turmoil for its investors. The pizza chain's got itself tangled in a class-action lawsuit, and it's the shareholders who're left with a bitter taste. Investors Cry Foul...

Tragedy Highlights Need for E-bike Safety Overhaul

A Dire Wake-Up Call in the East Village We're staring hard at a heartbreaking mess in the East Village. A 15-year-old girl lost her life while riding an electric Citi Bike, hit by an industrial truck. Let's not dance around it—this is a gut punch, the kind you never want to ever hear about, and one that comes with a bitter flavor of 'what if?' Age Verification: A...

Why Liver Nurture Taps into Health Sector Trends

Liver Wellness: A Sector on the Rise Remember when everyone was all about heart health and cholesterol levels? Seems like these days, folks have shifted their focus a bit south—right to the liver. It's no surprise, really. With our modern diet and lifestyle choices squeezing the life out of this hard-working organ, people are on the hunt for ways to give it the TLC it...

USPS Rolls Out Christmas Cookie Stamps Nationwide

USPS Delivers Nostalgia with Cookie-Themed Stamps Let's talk stamps, folks. The U.S. Postal Service has rolled out its newest Christmas Cookies Forever stamps, bringing a dash of sugary nostalgia to mailboxes nationwide. The release was celebrated at the Smithsonian National Postal Museum, spotlighting a tradition as sweet as the sugar cookies themselves. These aren't...

Qatar Foundation Spurs Sport-Driven Empowerment Moves

Here we go, diving into the serious talk of the moment: sports pushing boundaries to uplift society's underdogs. Envision yourself in the halls of Wilton Park, where the thinkers, the dreamers, and the doers convened in the name of change. Qatar Foundation ain't just sitting pretty; they're championing the cause to harness sport for impactful social threads across the...

Med Spa Visits: Key Insights from Lindsey Smith

Moving Beyond the Fear Factor Stepping into a med spa for the first time can be nerve-wracking, especially if you're unsure of what to expect. Lindsey Smith, an expert from Flawless Med Spa in Bryant, Arkansas, knows just how critical it is to navigate this terrain with clarity. Her approach emphasizes building a foundation of trust and understanding from the get-go. Fear...